First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 1, 2006, Pages 20-24

  Cheung, Rex ^a   Tucker, Susan L ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Kinetics; Overall survival; Prostate cancer; PSA; Radiotherapy

Indexed keywords

ANTIGENS; PARAMETER ESTIMATION; PATIENT MONITORING; REGRESSION ANALYSIS; SALVAGING; TUMORS;

KINETICS; OVERALL SURVIVAL; PROSTATE CANCER; PSA; RECURSIVE PARTITIONING ANALYSIS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIATION DOSE; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; REGRESSION ANALYSIS; TIME FACTORS;

EID: 33746825891     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.04.028     Document Type: Article

References (26)

1. Soloway M., and Roach III M. Prostate cancer progression after therapy of primary curative intent. A review of data from prostate-specific antigen era. Cancer 104 (2005) 2310-2322
2. Shipley W.U., Desilvio M., Pilepich M.V., et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer. A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64 (2006) 1162-1167
3. Stephenson A.J., and Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23 (2005) 8198-8203
4. Kamat A.M., Rosser C.J., Levy L.B., et al. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63 (2004) 1132-1137
5. Pickles T. Initiative. BCCAPCO: Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359
6. American Society for Therapeutic Radiology, and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
7. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
8. Vicini F.A., Kestin L.L., and Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 553-561
9. Kattan M.W., Fearn P.A., Leibel S., et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 48 (2000) 1469-1474
10. Horwitz E.M., Uzzo R.G., Hanlon A.L., et al. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 169 (2003) 2153-2157
11. Takamiya R., Weinberg V., Young C.D., et al. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 56 (2003) 1073-1078
12. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies. What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355-367
13. Pickett B., Kurhanewicz J., Coakley F., et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1047-1055
14. Pollack A., and Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39 (1997) 1011-1018
15. Cheung R., Tucker S.L., Lee A.K., et al. The dose response characteristics of low and intermediate risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 993-1002
16. Zhou P., Chen M.H., McLeod D., et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
17. Bates A.T., Pickles T., and Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 148-153
18. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
19. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168 (2002) 2001-2005
20. Kamat A.M., Babaian K., Cheung M.R., et al. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170 (2003) 1860-1863
21. Cox J.D., Gallagher M.J., Hammond E.H., et al., American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer. Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 17 (1999) 1155
22. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
23. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
24. Cavanaugh S.X., Fuller C.D., Kupelian P.A., et al. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prostatic Dis 8 (2005) 353-358
25. Nickers P., Albert A., Waltregny D., et al. Prognostic value of PSA nadir
26. Barnes A.S., Haker S.J., Mulkern R.V., et al. Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology 66 (2005) 1319